Chang Xu

机构：Huaian First People’s Hospital, Nanjing Medical University · ORCID：0000-0002-7726-902X

发表论文 23 篇 · 总被引 192 次 · h-index 9

代表论文

• LncRNA CDKN2B-AS1 promotes the progression of ovarian cancer by miR-143-3p/SMAD3 axis and predicts a poor prognosis (2020 · Neoplasma · 被引 30)
• Prediction of lung cancer risk in Chinese population with genetic‐environment factor using extreme gradient boosting (2022 · Cancer Medicine · 被引 29)
• Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma (2021 · BioMed Research International · 被引 19)
• Regulatory mechanism of lncRNA NORAD on proliferation and invasion of ovarian cancer cells through miR-199a-3p. (2020 · PubMed · 被引 19)
• SLAMF6/Ly108 promotes the development of hepatocellular carcinoma via facilitating macrophage M2 polarization (2022 · Oncology Letters · 被引 17)
• Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma (2020 · Disease Markers · 被引 17)